New Osteoporosis Guidelines
|
|
- Theresa Wilson
- 6 years ago
- Views:
Transcription
1 New Osteoporosis Guidelines New Osteoporosis Guidelines Released to Help Improve Australia s Bone Health Research Bites: DXA Rates in Men Still Falling Significantly Behind Women Vitamin D and Bone Health News Update Medical issue AUTUMN 2017
2 2 New Osteoporosis Guidelines Released to Help Improve Australia s Bone Health Osteoporosis Australia in collaboration with the Royal Australian College of General Practitioners (RACGP) are confident that new osteoporosis guidelines released in March will assist general practitioners to improve the bone health of Australian patients. The new clinical guidelines update the previous edition and include important developments over the past 6 years such as progress in osteoporosis care, including the introduction of a new medication, further clinical trial evidence for existing medications and an expanded evidence base for other interventions. The new guidelines will provide general practitioners with the expert guidance needed to help improve Australia s bone health. RACGP President Dr Bastian Seidel said about 4.74 million Australians over the age of 50 have osteoporosis or osteopenia and most of these patients will turn to their GP for support. This is why the new osteoporosis guidelines provide GPs with timely and much needed expert guidance to better detect, diagnose, and manage patients with osteoporosis. It will take away the ambiguity that has previously been associated with osteoporosis management. It is estimated there will be over 160,000 fractures due to poor bone health in Osteoporosis Australia CEO Greg Lyubomirsky said once a patient has broken a bone from a minor incident there is no time to wait. The underlying cause of that break should be investigated urgently and the patient may require treatment to minimise the risk of the next fracture occurring. We also encourage people with risk factors for osteoporosis to speak to their doctor because being pro-active can help prevent that first broken bone. The clinical guidelines were updated as a working partnership between Osteoporosis Australia and the RACGP. Osteoporosis Australia project managed a working group of Australian bone health experts, led by Chair of the Osteoporosis Guideline Committee Professor Peter Ebeling AO. The committee reviewed the current evidence and made clear recommendations for the diagnosis, treatment and prevention of osteoporosis. The guideline was then critically reviewed, endorsed and then published by the RACGP. Too few people with important risk factors for osteoporosis are investigated or treated. GPs play a Welcome This issue features the announcement of the first revision of the RACGP osteoporosis guidelines. With the rapid progress made in the field of osteoporosis, it was high time to update the old guidelines and provide medical practitioners with a current summary of the evidence. Apart from the useful executive summary and flow-chart, the new guidelines contain a number of evidence-based recommendations for osteoporosis diagnosis and treatment. Importantly, the guidelines now also provide information of how to deal with osteoporosis in patients with breast and prostate cancer, and advice on the use of fracture risk calculators. I encourage you to have a look at the revised guidelines, which are probably the most up-to-date worldwide (at least for the moment). I also urge you read Professor Mason s brief and concise review on Vitamin D and Bone Health, which summarises all you need to know about the sunshine hormone. Prof Markus Seibel
3 New osteoporosis guidelines released to help improve Australia s bone health (Cont.) front-line role in osteoporosis management and these new guidelines create a real opportunity for improving detection rates in general practice and reduce the burden of fractures. Importantly, fewer than 20 percent of patients who sustain a fracture due to osteoporosis are currently treated, despite effective treatments being available. So we need to improve this, Professor Ebeling said. More specific guidance for exercise to prevent bone loss and reduce fracture risk Updated recommendations for osteoporosis medication on PBS listed for both men and women Advice on the use of on-line fracture risk calculators to aid GP decision-making Recommendations around the appropriate use of calcium and vitamin D supplements Clearer guidance on treatment duration and monitoring Professor Ebeling also stated that if patients present with an osteoporotic fracture or risk factors for osteoporosis, action can be taken. GPs are critically poised to take up the challenge presented by osteoporosis and become champions of change to close the existing evidence-treatment gap. We are confident these guidelines will assist GPs as we aim to further reduce overall fracture rates in Australia, Dr Seidel said. Full clinical guidelines are free and accessible at Osteoporosis Australia and RACGP websites. To view and download visit The new guidelines contain a number of key highlights including: 42 evidence-based and consensus recommendations have been developed 2-page summary, with flowchart, for easy use by busy GPs Clearer directions for osteoporosis testing, diagnosis and treatment New recommendations for preventing and treating osteoporosis in people with breast and prostate cancer Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age 2nd edition Healthy Profession. Healthy Australia. Osteoporosis risk assessment, diagnosis and management Recommendations restricted to postmenopausal women and men aged >50 years Minimal trauma hip or vertebral fracture DXA to establish baseline BMD recommended but not essential Initiate treatment with anti-osteoporosis medication» Bisphosphonates (Grade A)» Denosumab (Grade A women, Grade B men)» Oestrogen replacement therapy (Grade A)» Strontium ranelate second line only (Grade A) BMD Bone mineral density DXA Dual energy X-ray absorptiometry HIV Human immunodeficiency virus MBS Medicare Benefits Schedule MGUS Monoclonal gammopathy of undetermined significance PPIs Proton pump inhibitors SSRIs Selective serotonin reuptake inhibitor Minimal trauma fracture at any other site * No history of minimal trauma fracture DXA of spine and proximal femur (Grade A) T-score 1.5 Where appropriate» Implement falls reduction strategies (Grade A)» Encourage exercise participation (Grade A)» Modify diet, smoking and alcohol intake (Grade C)» Provide education and psychosocial support (Grade D) T-score > 1.5 Refer for specialist review * Excluding fingers and toes Qualifies for MBS reimbursement of BMD testing Consensus recommendation. The MBS reimburses costs for measurement of BMD testing in any person aged 70 years See other guidelines specific to glucocorticoid treatment for more information and recommendations regarding glucocorticoid use and risk of osteoporosis and fracture Treatment of an underlying condition may improve bone strength Aged 70 years (Grade D Consensus) T-score 2.5? Yes No Initiate treatment with anti-osteoporosis medication» Bisphosphonates (Grade A)» Denosumab (Grade A women, Grade B men)» Oestrogen replacement therapy (Grade A)» Strontium ranelate second line only (Grade A) Where appropriate» Implement falls reduction strategies (Grade A)» Encourage exercise participation (Grade A)» Modify diet, smoking and alcohol intake (Grade C)» Provide education and psychosocial support (Grade D) Assess risk factor profile (Grade B) Major risk factors that qualify for MBS reimbursement of DXA Non-modifiable Diseases or conditions Medications (large effect)» Parental history of fracture» Rheumatoid arthritis» Glucocorticoids Modifiable and lifestyle» Hyperthyroidism (>3 months 7.5 mg/day)» Premature menopause» Hyperparathyroidism» Excess thyroid hormone replacement» Hypogonadism» Chronic kidney disease» Aromatase inhibitors» Multiple falls» Chronic liver disease» Anti-androgen therapy» Low physical activity or immobility» Coeliac disease or malabsorption Medications (modest effect)» Low body weight» Diabetes mellitus» SSRIs» Low muscle mass and strength» Myeloma or MGUS» Anti-psychotics» Poor balance» Organ transplant» Thiazolidenediones» Protein or calcium undernutrition» Bone marrow transplant» Anti-epileptic medications» Smoking» HIV infection» PPIs» Alcohol >2 standard drinks/day» Depression» Vitamin D insufficiency DXA of spine and proximal femur (Grade A) Estimate absolute fracture risk Garvan Fracture Risk Calculator or FRAX (Grade D Consensus) High 10-year risk of fracture Hip fracture >3%, any fracture >20% OR T-score 2.5 Low risk of fracture Treatment not recommended GP Guidelines and 2-page summary with management algorithm and practice tips
4 4 researchbites Research Review by Dr Lisa Croucher (OA Scientific Advisor) DXA Rates in Men Still Falling Significantly Behind Women A new analysis of Medicare data has revealed a worrying lack of awareness of fracture risk in Australian men. Publishing in the December 2016 issue of the Journal of Clinical Densitometry (doi: /j.jocd ), researchers from Sydney s Garvan Institute of Medical Research and St Vincent s Hospital analysed Medicare Item Statistic reports of DXA scans in males and females between 1995 and 2015, broken down by age group. In general, the picture is encouraging, with DXA claims increasing steadily in both men and women over the 20-year period. A jump in claims in 2007 for the over 65s reflects improvements in Medicare provision it was in 2007 that all individuals over the age of 70 became eligible for subsidised DXA. However, the research has highlighted the continued disparity in bone health management between men and women. Although male DXA rates have improved over the past 20 years, men are still not being tested in the same numbers as women. From 2007, more than twice as many women in the age group were tested than men of the same age, and in the age group, three times more women were tested. Interestingly, testing in men aged 85 and over appears to be responsible for a large proportion of the rise in male testing rates since This finding is important, because although men over 85 are at higher individual risk of fracture (as are women), the bulk of fractures in the male population actually occur in the age group, reflecting male demographic age distribution in Australia. The authors suggest that increased testing in this very elderly population reflects increasing awareness of high fracture risk in this age group by health care professionals. The reasons for the persistently poor DXA overall testing rates in men remain unclear. The report s authors suggest a perception by health care professionals that osteoporosis is uncommon in men, despite data demonstrating that a man of 60 has a 29% chance of a fracture in his remaining lifetime. Other contributory factors may be mens lower interest in their personal health, social isolation or depression. Specific educational strategies to target the age group where fracture prevalence is greatest may improve osteoporosis awareness and result in better outcomes for men.
5 5 Vitamin D and Bone Health Professor Rebecca Mason Head of Physiology, School of Medical Sciences, Sydney Medical School Deputy Director, Bosch Institute With increasing uptake of effective treatments for osteoporosis, it is easy to forget the importance of lifestyle interventions vitamin D, calcium and weight-bearing exercise in optimising bone health throughout life as well as optimising responses to specific osteoporosis treatments. This article will focus on vitamin D. The basic physiology indicates that vitamin D, actually the hormone made from vitamin D, 1,25-dihydroxvitamin D, is important for active absorption of calcium from the gut. The calcium, of course, has to be ingested in the first place. Dietary calcium, absorbed through the actions of vitamin D metabolites, helps to replace calcium lost each day in the urine, gut and sweat. If this process works well, it means that bone, which is the major store of calcium in the body, does not need to be raided to maintain blood calcium, despite these daily losses. As people get older, renal losses of calcium become larger and efficiency of calcium absorption in the gut is reduced. At the same time, frail older people and people who need to live in institutions where care is provided, do not get out in the sun much to make vitamin D in skin (there is not much vitamin D in most unfortified foods) and mostly cannot be persuaded to do so, even with assistance. 1 They often have a poor appetite, resulting in less than optimal calcium intake (1300mg/day in older people) 2 and poor intake of protein, which is also important for bone health. Vitamin D is also a key factor in optimal muscle function, which affects propensity to fall. 3 There have been numerous meta-analyses of randomised controlled trials of patients given vitamin D with or without calcium with fractures as the outcome. The consensus views are that the combination of vitamin D and calcium (see physiology above) does have a modest, but significant effect to reduce fractures in older, susceptible people (4-7). Trials involving vitamin D are difficult to do well, since vitamin D is already present in the body. If the person has enough vitamin D, whatever enough is, and a target of a minimum of 50nmol/L, higher at end of summer to allow for winter drop is recommended, 8 giving more vitamin D will not produce any benefit. Not surprisingly therefore, the best evidence of efficacy in fracture reduction, for vitamin D with calcium come from studies in markedly vitamin D-deficient patients at high risk of fracture. 9 There is also evidence that some of the more specific treatments for osteoporosis do not work as well if patients are vitamin D deficient. 10 Most of the clinical trials of osteoporosis treatments are undertaken in patients given vitamin D and calcium supplements. Low vitamin D status may increase incidence of hypocalcemia in patients given intravenous bisphosphonate or denosumab, though usually for conditions such as metastatic malignancy, where high doses of these agents are used. 11,12 Guidance on vitamin D testing has stressed that only groups at-risk of vitamin D deficiency require investigation, for example: severe lack of sun exposure for cultural, medical or occupational reasons, malabsorption, signs or symptoms of osteoporosis or osteomalacia, hyperparathyroidism, very dark skin, taking medication known to impact D levels (eg: anticonvulsants) or infants of vitamin D deficient mothers. When dealing with older or frail people, where advice to go into the sun for brief periods, most days, 8 is unlikely to be heeded or practical, 1 vitamin D supplements are an alternative. A baseline vitamin D status measurement (actually measuring 25-hydroxyvitamin D (25(OH)D), the major circulating vitamin D metabolite), in at risk patients, may be helpful in monitoring the effect of therapy. Daily treatment with around 1000IU (25mcg) of vitamin D3 (cholecalciferol, the same compound made in skin and the form of vitamin D in nearly all supplements now available in Australia) should be enough to raise 25(OH)D levels to above 50nmol/L, but higher doses may be needed in some patients. 8 It takes over 3 months for 25OHD to reach a new steady state in blood after starting supplements or after a change in dose, so there is little point in ordering a follow-up vitamin D assay earlier than this. 8 Compliance with vitamin D supplementation, even in clinical trials, is poor. 5 For this reason, alternatives to daily vitamin D treatment have been tested. Once yearly high doses of 500,000IU (12,500mcg) did not cause hypercalcaemia, but actually increased the risk of falls with a non-significant increase in fractures, for reasons that are unclear. 13 If vitamin D supplements are required and daily dosing is impractical, weekly doses of vitamin D are an option that may enhance the patient compliance. These formulations are now available in Australia. References available upon request.
6 6 NEWS UPDATE World Congress breaks record The World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases was hosted by the IOF and ESCEO on March in Florence. The congress attracted a record number of abstracts and over 4,000 delegates. As part of the congress Professor John Kanis, President of the International Osteoporosis Foundation, presented awards to seven individual members for their dedication to the work of IOF and commitment to advancing education and awareness in their countries and region. The Asia Pacific award was presented to Professor Kerrie Sanders team leader of musculoskeletal science, health economics and nutrition at the Institute for Health and Ageing, Melbourne; Honorary position as Principal Fellow at the University of Melbourne and member of the Medical and Scientific Advisory committee of Osteoporosis Australia and the IOF Committee of Scientific Advisors. The congress was preceded by the bi-annual Worldwide Conference of Osteoporosis Patient Societies representing over 30 countries from all regions and including Osteoporosis Australia. The Know Your Bones consumer program launched by Osteoporosis Australia was featured among other success stories from patient societies. Greg Lyubomirsky, CEO of Osteoporosis Australia said it is encouraging to see the programs being introduced in other parts of the world and share ideas from what has worked. Professor Kerrie Sanders Reaching General Practice The start of the new triennium in 2017 and the release of new clinical guidelines for osteoporosis management means the topic of osteoporosis will feature in the scientific programs of large GP conferences around Australia. In particular the HealthEd Women and Children s Health Update, GPCE Conferences and the RACGP annual conference. Update regarding treatment Servier are alerting GPs about the change in availability of strontium ranelate (trade name Protos) in Australia. The product will be discontinued permanently and only limited stock will be available worldwide beyond August The notification recommends that no new patients should be initiated on the treatment. Servier states the decision is not related to a quality of safety issue in Australia or internationally, it is due to a significant reduction in global demand for the treatment (Protos). Do your patients need information? Direct patients to the Osteoporosis Australia website or tollfree patient info number MEDICAL ISSUE AUTUMN 2017 Medical Editor: Prof Markus Seibel Editorial: Melita Daru Ainslie Bishop Advertising: Melita Daru Osteoblast is a publication of: Osteoporosis Australia ABN PO Box 550 Broadway NSW 2007 National office National hotline Copyright Osteoporosis Australia Except as provided by the Copyright Act 1968, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior written permission of the publisher. Resources for General Practice Information and resources for general practice can be accessed online in the GP section of the Osteoporosis Australia website, located under the Healthcare Professional section.
Know Your Bones. Know Your Bones Launches Nationally Treatment Adherence and Fracture Risk Reduction News Update
Know Your Bones Know Your Bones Launches Nationally Treatment Adherence and Fracture Risk Reduction News Update Medical issue special edition 2016 2 Know Your Bones Launches Nationally Osteoporosis Australia
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationA JOINT INITIATIVE FOR FRACTURE PREVENTION. Know Your Bones Community Risk Report October 2018
A JOINT INITIATIVE FOR FRACTURE PREVENTION Forewords Greg Lyubomirsky CEO Osteoporosis Australia 1 Know Your Bones was developed to help Australians understand their risk of poor bone health and discuss
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationOsteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance
Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationTaking Bone Health Seriously
Taking Bone Health Seriously Medical issue Autumn 2014 New Report reveals Australia s Poor Bone Health Research Bites: Research Review by Dr Lisa Croucher Patient Case Study: Doctors Comment on Patient
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationPathway from Fracture or Risk Factor to Treatment
Appendix 6A - Guidance on Diagnosis and Management of Osteoporosis Pathway from Fracture or Risk Factor to Treatment Fragility Fracture = fracture sustained from a low energy fall from standing height
More informationReal Men Build Their Strength From Within
Real Men Build Their Strength From Within The State of Men s Bone Health Research Bites: Research Review by Dr Lisa Croucher Hypogonadism and Osteoporosis Latest Research Awards Healthy Bones Australia:
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationGuidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals
WA.DRUG EVALUATION PANEL Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals Introduction Osteoporotic fracture-related hospitalisations impose a substantial financial
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationAll about. Osteoporosis
All about Osteoporosis What is osteoporosis? Osteoporosis literally means porous bone. It is a condition that causes bones to become thin and fragile, decreasing bone strength and making them more prone
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationOsteoporosis The Silent Disease
Joel Johnson, Yr, Subtask, Biology ER., 7/9/5 Osteoporosis The Silent Disease What is Osteoporosis? Osteoporosis is a disease which causes bones to become brittle, which increases the risk of broken bones.
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationSCHEDULE 2 THE SERVICES. A. Service Specifications
SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy
More informationBone density scanning and osteoporosis
Bone density scanning and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationHIV and your Bones Osteopenia and Osteoporosis
Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia
More informationNICE SCOOP OF THE DAY FRAX with NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
NICE SCOOP OF THE DAY FRAX with NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Consultant/Advisor/Speaker for: o ActiveSignal, Amgen, AstraZeneca, Consilient
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationFRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
FRAX, NICE and NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Research funding and/or honoraria and/or advisory boards for: o ActiveSignal, Amgen, Bayer, Boehringer
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationPreliminary Programme
Preliminary Programme ICC SYDNEY w w w.iof-regional.org Organizer International Osteoporosis Foundation Secretariat www.humacom.com Submit your abstract now! PRE-CONFERENCE COURSE ACU North Sydney Campus
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationBreast Cancer Network Australia DXA bone mineral density survey May 2012
Breast Cancer Network Australia DXA bone mineral density survey May 212 I won't be having any more mineral density tests as I can't afford the high cost. Introduction Of the 14,2 women diagnosed with breast
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationAudit on follow-up of patients with primary Osteoporosis
Abstract Aim: To document the frequency of Dual-energy X- ray absorptiometry (DEXA) scanning and Rheumatology clinic follow-up visits of patients with primary osteoporosis, and compare these with recommended
More informationClosing the Care Gap in Osteoporosis ICE Conference 2015
Closing the Care Gap in Osteoporosis ICE Conference 2015 Pat McCarthy-Briggs RD, MHEd Thank You! What is osteoporosis? a systemic skeletal disease characterized by low bone mass and microarchitectural
More informationDEXA SCAN POLICY CRITERIA BASED ACCESS
DEXA SCAN POLICY Version: 1718.v2 Recommendation by: Somerset CCG Clinical Commissioning Policy Forum (CCPF) Date Ratified: 01 November 2017 Name of Originator/Author: Approved by Responsible Committee/Individual:
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationDumfries and Galloway. Treatment Protocol for Osteoporosis
Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 Multiple low trauma vertebral fractures in the absence of myeloma or metastatic disease. 2 T-score
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationMAN SHORTER CAN MAKE A HOW OSTEOPOROSIS. Ask your doctor if you have osteoporosis and if Prolia may be right for you. AND WHAT YOU CAN DO NEXT
Ask your doctor if you have osteoporosis and if Prolia may be right for you. Prolia is a prescription medicine used to increase bone mass in men with osteoporosis who: are at high risk for fracture, meaning
More informationBEST PRACTICE FRAMEWORK QUESTIONNAIRE
CAPTURE the FRACTURE BEST PRACTICE FRAMEWORK QUESTIONNAIRE INTRODUCTION Capture the Fracture invites Fracture Liaison Services (FLS) to apply for Capture the Fracture Best Practice Recognition programme.
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationDiscovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future.
Discovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future. *A fragility fracture is defined as a fracture caused by minimal trauma,
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper Quality standard topic: Osteoporosis Output: Prioritised quality improvement
More informationMake your. first break. your last.
www.iofbonehealth.org Make your first break your last WHAT IS OSTEOPOROSIS? Osteoporosis is a disease in which bones become more fragile and weak, leading to an increased risk of fractures (broken bones).
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationAnalyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness
Analyses of cost-effective BMD scanning and treatment strategies for generic alendronate, and the costeffectiveness of risedronate and strontium ranelate in those people who would be treated with generic
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis. Prevention and detection in general practice. Bones. Prevention. Prevention with lifestyle changes. Background. Objective.
Bones Dan Ewald Osteoporosis Prevention and detection in general practice Background Osteoporosis causes a large and growing health burden in Australia. Effective treatments are available, but these are
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationDISCLAIMER DO NOT DISTRIBUTE
DISCLAIMER The information contained in this presentation is not intended as a substitute for professional medical advice, diagnosis, or treatment. It is provided for educational purposes only. You assume
More informationOsteoporosis: assessing the risk of fragility fracture
Osteoporosis: assessing the risk of fragility fracture Issued: August 2012 NICE clinical guideline 146 guidance.nice.org.uk/cg146 NICE has accredited the process used by the Centre for Clinical Practice
More informationCosting statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationCalcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People
Calcium and Vitamin D Supplementation is an Ineffective Strategy for the Prevention of Fractures in Older People For the Motion: Professor Roger Francis, Institute for Ageing and Health, Newcastle University,
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationNSW & ACT. Osteoporosis costing NSW & ACT: A burden of disease analysis 2012 to 2022
NSW & ACT Authors Kerrie M Sanders, Jennifer J Watts, Julie Abimanyi-Ochom, Ghulam Murtaza Osteoporosis costing NSW & ACT: A burden of disease analysis 2012 to 2022 Osteoporosis costing NSW & ACT A burden
More information1. Adults; a. Risk factors. b. Who should be tested for vitamin D deficiency? c. Investigations. d. Who do we treat and how do we treat? 2.
Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management For Adults and Children Adapted from existing local guidance, National Osteoporosis Society Practical Guides and from Royal
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationMy joints ache. What is the difference between osteoporosis and osteoarthritis?
Osteoporosis What is osteoporosis? Osteoporosis means bones are less dense, more fragile, and at greater risk for breaking, even with small injuries. This problem often affects bones in the hip, spine,
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationSection 4. Scans and tests. How do I know if I have osteoporosis? Investigations for spinal fractures. Investigations after you break a bone
Section 4 Scans and tests How do I know if I have osteoporosis? Investigations for spinal fractures Investigations after you break a bone Investigations if you have risk factors Investigations for children
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationProlia 2 shots a year proven to help strengthen bones. next shot appointment
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com next shot appointment For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationEU Osteoporosis Report CYPRUS
EU Osteoporosis Report 2007-2008 CYPRUS Completed by: Dr Christodoulos Kaisis, M.D., Specialist. in Internal Medicine, G.P., M.P.H. Dr George Georgiades, M.D., Specialist. in Endocrinology OVERVIEW 2007
More informationThe Healthy Male. issue 63. Looking after the health of Australian men into the future CONTENTS. Winter 2017
The Healthy Male NEWSLETTER OF ANDROLOGY AUSTRALIA Australian Centre of Excellence in Male Reproductive Health Winter 2017 issue 63 CONTENTS 1 Looking after the health of Australian men into the future
More informationOsteoporosis and Lupus. Andrew Ruthberg, MD University Rheumatologists
Osteoporosis and Lupus Andrew Ruthberg, MD University Rheumatologists 1 Forget the medical terminology (osteoporosis, osteopenia, low bone mass, DEXA, DXA, T score etc) The bottom line is that you don
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationRecent advances in the management of osteoporosis
CONFERENCE SUMMARIES Clinical Medicine 2009, Vol 9, No 6: 565 9 Recent advances in the management of osteoporosis Juliet Compston Introduction Osteoporotic fractures are a major cause of morbidity and
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationProlia 2 shots a year proven to help strengthen bones.
For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven to help strengthen bones. Blythe Danner, Award winning actress taking Prolia. Prolia is
More informationDr Seeta Durvasula.
Dr Seeta Durvasula seeta.durvasula@sydney.edu.au 1 Avoid sun skin cancer risk Australia has highest rates of skin cancer in the world Epidemic of Vitamin D deficiency Lack of Vitamin D increases risk of
More information